Organoid engineering with microfluidics and biomaterials for liver, lung disease, and cancer modeling

• Published in: Acta biomaterialia Vol. 132; pp. 37 - 51
• Main Authors: Kim, Su Kyeom, Kim, Yu Heun, Park, Sewon, Cho, Seung-Woo
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 15.09.2021; Elsevier BV
• Subjects: Biomaterials; Biomedical materials; Cancer; Constraint modelling; Customization; Disease; Disease modeling; Drug development; Drug screening; Engineering; Life expectancy; Life span; Liver; Liver cancer; Liver diseases; Lung cancer; Lung diseases; Medicine; Microfluidics; Mimicry; Organoid; Organoids; Organs; Personalized medicine; Precision medicine; Organoid; Disease modeling; Personalized medicine; Drug screening; Microfluidics; Biomaterials
• ISSN: 1742-7061; 1878-7568
• DOI: 10.1016/j.actbio.2021.03.002

As life expectancy improves and the number of people suffering from various diseases increases, the need for developing effective personalized disease models is rapidly rising. The development of organoid technology has led to better recapitulation of the in vivo environment of organs, and can overcome the constraints of existing disease models. However, for more precise disease modeling, engineering approaches such as microfluidics and biomaterials, that aid in mimicking human physiology, need to be integrated with the organoid models. In this review, we introduce key elements for disease modeling and recent engineering advances using both liver and lung organoids. Due to the importance of personalized medicine, we also emphasize patient-derived cancer organoid models and their engineering approaches. These organoid-based disease models combined with microfluidics, biomaterials, and co-culture systems will provide a powerful research platform for understanding disease mechanisms and developing precision medicine; enabling preclinical drug screening and drug development. The development of organoid technology has led to better recapitulation of the in vivo environment of organs, and can overcome the constraints of existing disease models. However, for more precise disease modeling, engineering approaches such as microfluidics and biomaterials, that aid in mimicking human physiology, need to be integrated with the organoid models. In this review, we introduce liver, lung, and cancer organoids integrated with various engineering approaches as a novel platform for personalized disease modeling. These engineered organoid-based disease models will provide a powerful research platform for understanding disease mechanisms and developing precision medicine. [Display omitted]